9,067 reports of this reaction
3.8% of all INSULIN LISPRO reports
#2 most reported adverse reaction
INCORRECT DOSE ADMINISTERED is the #2 most commonly reported adverse reaction for INSULIN LISPRO, manufactured by Eli Lilly and Company. There are 9,067 FDA adverse event reports linking INSULIN LISPRO to INCORRECT DOSE ADMINISTERED. This represents approximately 3.8% of all 239,540 adverse event reports for this drug.
Patients taking INSULIN LISPRO who experience incorrect dose administered should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INCORRECT DOSE ADMINISTERED is moderately reported among INSULIN LISPRO users, representing a notable but not dominant share of adverse events.
In addition to incorrect dose administered, the following adverse reactions have been reported for INSULIN LISPRO:
The following drugs have also been linked to incorrect dose administered in FDA adverse event reports:
INCORRECT DOSE ADMINISTERED has been reported as an adverse event in 9,067 FDA reports for INSULIN LISPRO. This does not prove causation, but indicates an association observed in post-market surveillance data.
INCORRECT DOSE ADMINISTERED accounts for approximately 3.8% of all adverse event reports for INSULIN LISPRO, making it one of the most commonly reported side effect.
If you experience incorrect dose administered while taking INSULIN LISPRO, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.